Literature DB >> 25322683

Adenosine triphosphate-induced rabbit corneal endothelial cell proliferation in vitro via the P2Y2-PI3K/Akt signaling axis.

Junzhao Chen1, Chunyi Shao, Wenjuan Lu, Chenxi Yan, Qinke Yao, Mengyu Zhu, Ping Chen, Ping Gu, Yao Fu, Xianqun Fan.   

Abstract

PURPOSE: To investigate the effect of the ATP-P2Y2-PI3K/Akt signaling axis on promoting rabbit corneal endothelial cell (RCEC) proliferation in vitro.
METHODS: Five concentrations of adenosine triphosphate (ATP; 1, 10, 25, 50 and 100 μM) were added to RCECs, and the cell proliferation was detected using Cell Counting Kit-8 (CCK8) and Ki67 immunohistochemical staining. Other P2Y2 receptor agonists and antagonists were added to the cells, and the proliferation effect was evaluated using CCK8 to determine the involvement of the P2Y2 receptor. Changes in the expression of phosphorylated Akt in RCECs treated with different concentrations of extracellular ATP and the duration of extracellular ATP on Akt phosphorylation were investigated using Western blotting. The pharmacological profiles with or without the PI3K/Akt pathway inhibitors were also determined using Western blotting.
RESULTS: We found that 10 μM ATP strongly promoted RCEC proliferation in vitro. Additionally, 25 μM ATP had a proliferation effect, whereas other concentrations (1, 50 and 100 μM) had no effect compared with the control group. Selective P2Y2 receptor agonists (UTP, ATPγS and Ap4A) showed the same promotion effect, while P2Y2 antagonists and PI3K/Akt inhibitors inhibited the effect of ATP. Moreover, phosphorylated Akt could be induced by the addition of extracellular ATP at all five concentrations and lasted for 1 h. This phosphorylation was prevented by PI3K/Akt inhibitors and a P2Y2 antagonist.
CONCLUSIONS: These findings showed that 10 μM ATP markedly promoted RCEC proliferation via the P2Y2-PI3K/Akt signaling axis.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25322683     DOI: 10.1159/000365654

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  7 in total

1.  P2Y2 Nucleotide Receptor Prompts Human Cardiac Progenitor Cell Activation by Modulating Hippo Signaling.

Authors:  Farid G Khalafalla; Steven Greene; Hashim Khan; Kelli Ilves; Megan M Monsanto; Roberto Alvarez; Monica Chavarria; Jonathan Nguyen; Benjamin Norman; Walter P Dembitsky; Mark A Sussman
Journal:  Circ Res       Date:  2017-09-18       Impact factor: 17.367

2.  P2X7 receptors and Fyn kinase mediate ATP-induced oligodendrocyte progenitor cell migration.

Authors:  Ji-Feng Feng; Xiao-Fei Gao; Ying-Yan Pu; Geoffrey Burnstock; Zhenghua Xiang; Cheng He
Journal:  Purinergic Signal       Date:  2015-06-23       Impact factor: 3.765

3.  Inhibition of LY294002 in retinal neovascularization via down-regulation the PI3K/AKT-VEGF pathway in vivo and in vitro.

Authors:  Yu Di; Xiao-Long Chen
Journal:  Int J Ophthalmol       Date:  2018-08-18       Impact factor: 1.779

4.  The P2Y2 Receptor Interacts with VE-Cadherin and VEGF Receptor-2 to Regulate Rac1 Activity in Endothelial Cells.

Authors:  Zhongji Liao; Chen Cao; Jianjie Wang; Virginia H Huxley; Olga Baker; Gary A Weisman; Laurie Erb
Journal:  J Biomed Sci Eng       Date:  2014-12-01

5.  Tributyrin Plays an Important Role in Regulating the Growth and Health Status of Juvenile Blunt Snout Bream (Megalobrama amblycephala), as Evidenced by Pathological Examination.

Authors:  Hualiang Liang; Ke Ji; Xianping Ge; Bingwen Xi; Mingchun Ren; Lu Zhang; Xiaoru Chen
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

Review 6.  Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.

Authors:  Mazen Shihan; Tatyana Novoyatleva; Thilo Lehmeyer; Akylbek Sydykov; Ralph T Schermuly
Journal:  Int J Environ Res Public Health       Date:  2021-10-20       Impact factor: 3.390

7.  Effects of LY294002 on the function of retinal endothelial cell in vitro.

Authors:  Yu Di; Xiao-Long Chen
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.645

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.